DEF: Salarius Pharmaceuticals Seeks Shareholder Approval for Reverse Stock Split and Significant Equity Issuance to Avoid Nasdaq Delisting

Salarius Pharmaceuticals, Inc. is calling a Special Meeting of Stockholders to vote on a reverse stock split to regain Nasdaq compliance and to approve the issuance of shares under a $10 million equity line of credit, which could lead to substantial shareholder dilution.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) will hold a Special Meeting of Stockholders on July 8, 2025, to address critical Nasdaq listing compliance issues.
• Shareholders will vote on a Reverse Stock Split Proposal, allowing the Board to effect a reverse stock split at a ratio between 1:4 and 1:40, aimed at increasing the stock price to meet Nasdaq's $1.00 minimum bid price requirement.
• The company received a Nasdaq notice on April 23, 2025, for non-compliance with the $1.00 minimum bid price rule, and is not eligible for a standard compliance period due to a prior reverse stock split within the last year.
• Salarius also received a Nasdaq notice on March 26, 2025, for failing to maintain a minimum of $2.5 million in stockholders' equity, and Nasdaq will not entertain a compliance plan for this issue due to the bid price non-compliance.
• The company has appealed the delisting determination and plans to present its strategy to regain compliance, including the reverse stock split and addressing the equity standard in connection with a planned merger with Decoy Therapeutics, Inc. and future draw-downs from an equity line.
• Shareholders will also vote on the Nasdaq 20% Issuance Proposal to approve the issuance of shares under a Securities Purchase Agreement, dated December 12, 2024, with C/M Capital Master Fund, LP, without giving effect to the 19.99% exchange cap.
• This equity line allows Salarius to sell up to $10 million of common stock to C/M Capital Master Fund, LP; as of May 13, 2025, approximately $740,500 has been raised through the issuance of 286,772 shares.
• If the Nasdaq 20% Issuance Proposal is approved, the remaining approximately $9,259,500 could be raised, potentially resulting in the Purchaser owning approximately 9.3 million shares, or 81% of the outstanding common stock (based on a $1.00/share price and May 13, 2025, outstanding shares), leading to significant dilution for existing shareholders.
• The Adjournment Proposal seeks approval to adjourn the Special Meeting if necessary to solicit additional proxies for the other two proposals.
• As of May 13, 2025, there were 2,127,286 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the company's precarious financial position, imminent Nasdaq delisting threat, and the necessity of a reverse stock split and highly dilutive equity financing. While the capital raise provides a lifeline, the terms and the underlying issues (Nasdaq non-compliance) are significant red flags for investors.

Negatives

• The company is currently non-compliant with Nasdaq's minimum bid price requirement ($1.00 per share) and minimum stockholders' equity requirement ($2.5 million).
• Salarius is not eligible for the standard 180-day compliance period for the bid price rule due to a reverse stock split within the prior one-year period, indicating persistent issues.
• Nasdaq will not entertain a compliance plan for the equity standard non-compliance due to the bid price issue, forcing the company to address both before a Hearings Panel.
• Failure to obtain shareholder approval for the Nasdaq 20% Issuance Proposal would prevent the company from fully utilizing the $10 million equity line, potentially forcing it to seek alternative, less advantageous financing or face liquidation/bankruptcy.
• The potential issuance of shares under the equity line could result in substantial dilution for existing shareholders, with the Purchaser potentially owning 81% of the outstanding common stock if the full amount is drawn down at $1.00 per share.
• The reverse stock split, while necessary for Nasdaq compliance, carries risks such as not proportionately increasing the market price, harming liquidity, and increasing the number of authorized but unissued shares that could be used for dilutive financing or anti-takeover measures.

Risks

• The company's common stock may be delisted from the Nasdaq Capital Market if it fails to regain compliance with listing rules, leading to limited market quotations, 'penny stock' designation, reduced trading activity, and decreased ability to raise future financing.
• There is no assurance that a favorable decision from the Nasdaq Hearings Panel will be obtained or that the company's securities will remain listed on The Nasdaq Capital Market.
• The reverse stock split may not increase the market price per share proportionately with the ratio of the combination, and the total market capitalization could be lower after the split.
• The liquidity of the common stock may be harmed by the reverse stock split due to a reduced number of outstanding shares.
• The increased number of authorized but unissued shares post-reverse split could be used in dilutive equity financing transactions or to oppose hostile takeover attempts.
• The reverse stock split may result in some stockholders owning 'odd lots' (less than 100 shares), which may be more difficult or costly to sell.
• If the Nasdaq 20% Issuance Proposal is not approved, the company may be unable to fully satisfy its ongoing business needs, potentially impacting future operating results and leading to liquidation or bankruptcy proceedings.
• The sale into the public market of shares issued under the Purchase Agreement could materially and adversely affect the market price of the common stock.

Future Outlook

The company's future outlook is heavily dependent on regaining Nasdaq listing compliance, which hinges on the successful implementation of a reverse stock split and the approval of a significant equity issuance. The planned merger with Decoy Therapeutics, Inc. is also a key component of their strategy to regain compliance with the equity standard. Failure to achieve these objectives could lead to delisting, severely impacting the company's ability to raise capital and continue operations.

Management Comments

• "Our Board is seeking stockholder approval of the Reverse Stock Split with the primary intent of increasing the price of our common stock in order to meet the Nasdaqs minimum price per share criteria for continued listing on that exchange."
• "The Board believes that stockholder approval of the range of reverse stock split ratios (as opposed to approval of a single reverse stock split ratio) provides the Board with maximum flexibility to achieve the purpose of a reverse stock split..."
• "At the appeal before the Hearings Panel, we intend to present our plans to regain compliance with the Minimum Bid Price Requirement, including the implementation of a reverse stock split (shareholder approval to be sought at the Special Meeting) and the Equity Standard in connection with the Companys planned merger transaction with Decoy Therapeutics, Inc."
• "Our ability to successfully implement our business plans and ultimately generate value for our stockholders is dependent upon our ability to raise capital and satisfy our ongoing business needs."
• "If we are unable to issue Purchase Shares pursuant to the Purchase Agreement, we may be unable to fully satisfy our ongoing business needs on the terms or timeline we anticipate, if at all, the effect of which could materially and adversely impact future operating results, and may result in the Company seeking liquidation or bankruptcy proceedings."

Industry Context

Salarius Pharmaceuticals operates in the biotechnology/pharmaceuticals industry, which is highly capital-intensive and often relies on equity financing to fund research, development, and operations. Companies in this sector frequently face challenges in maintaining Nasdaq listing requirements, particularly regarding minimum bid price and stockholders' equity, especially if their clinical programs or commercialization efforts face setbacks or require significant ongoing investment. Reverse stock splits and equity lines of credit are common tools used by smaller biotech firms to address these challenges and secure necessary funding, though they often come with significant dilution for existing shareholders.

Corporate Governance

Legal Proceedings

• The company has appealed Nasdaq's delisting determination and will present its case before a Nasdaq Hearings Panel.

Stakeholder Impact

• **Shareholders**: Will experience a reduction in the number of shares held due to the reverse stock split, though their percentage ownership will remain largely the same (except for fractional shares). Will face significant dilution of ownership and voting rights if the Nasdaq 20% Issuance Proposal is approved and the equity line is fully utilized. Risk of delisting could severely impact share value and liquidity.
• **Employees**: The company's ability to continue operations and fund its business plans, including equity incentive awards, is dependent on successful capital raises and Nasdaq listing, which directly impacts job security and equity value.
• **Creditors**: The company's financial stability and ability to meet obligations are tied to its capital-raising efforts and continued listing, which affects its creditworthiness.
• **Customers/Partners (Decoy Therapeutics)**: The planned merger with Decoy Therapeutics is crucial for the company's strategy to regain Nasdaq compliance, indicating a significant reliance on this partnership for future viability.

Next Steps

• Hold a Special Meeting of Stockholders on July 8, 2025, to vote on the Reverse Stock Split Proposal, Nasdaq 20% Issuance Proposal, and Adjournment Proposal.
• If approved, the Board will determine the exact ratio and effective time for the reverse stock split within twelve months from the Special Meeting date.
• The company intends to present its plans to regain Nasdaq compliance (including the reverse stock split and addressing the equity standard) before a Nasdaq Hearings Panel.
• The company plans to proceed with the planned merger transaction with Decoy Therapeutics, Inc., which is linked to regaining compliance with the Equity Standard.
• If the Nasdaq 20% Issuance Proposal is approved, the company may continue to sell shares to C/M Capital Master Fund, LP under the equity line of credit for working capital and general corporate purposes.
• File a current report on Form 8-K with the SEC within four business days after the Special Meeting to publish preliminary or final voting results.

Key Dates

Recommendation

Keywords

Salarius Pharmaceuticals, SLRX, SEC filing, DEF 14A, Proxy Statement, Special Meeting, Reverse Stock Split, Nasdaq Listing Rules, Delisting, Minimum Bid Price, Stockholders' Equity, Equity Line of Credit, C/M Capital Master Fund, Share Dilution, Corporate Governance, Biotechnology, Pharmaceuticals, Capital Raise, Decoy Therapeutics Merger